Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Major Depressive Disorder (mdd) Clinical Trials

Reviewed by TrialFinderData Editorial Team · Updated

9 recruiting trials for Major Depressive Disorder (mdd). Eligibility criteria explained in plain English.

TrialFinderData lists 9 Major Depressive Disorder (mdd) clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.

Across the trials that carry a phase, Phase 2 is the largest group at 75% (3 studies); the largest phase groups are Phase 2: 3, Phase 3: 1.

Research is led by Draig Therapeutics Ltd (2), Tonix Pharmaceuticals, Inc. (1), Cybin IRL Limited (1), among the most active sponsors registered for these trials.

The most frequently studied intervention is DT-101 (drug, 3 trials), followed by Placebo, TNX-102 SL.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
9
Total Trials
9
Recruiting Now
1
Phase 3 Trials
8
Sponsors

Track Major Depressive Disorder (mdd) trials

Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGPhase 2NCT07610473

A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression

In this study, researchers will learn more about a study drug called DT-101 in participants with Major Depressive Disorder (MDD), a form of depression. The goal of this clinical...

Sponsor: Draig Therapeutics LtdEnrolling: 1182 locations
RECRUITINGPhase 2NCT07621237

A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)

The goal of this clinical trial is to learn if a drug called TNX-102 SL works to treat moderate to severe major depressive disorder in adults. It will also learn about the safety...

Sponsor: Tonix Pharmaceuticals, Inc.Enrolling: 36020 locations
RECRUITINGPhase 2NCT07300969

A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression

The goal of this clinical trial is to learn if DT-101 can treat depression in adults. The effect of DT-101 will be compared to placebo. Subjects will attend the clinic every...

Sponsor: Draig Therapeutics LtdEnrolling: 30020 locations
RECRUITINGPhase 3NCT06793397

A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

The purpose of this study is to determine the efficacy, safety and tolerability of CYB003 compared to matching placebo as adjunctive treatment in patients with MDD. For more...

Sponsor: Cybin IRL LimitedEnrolling: 33020 locations
RECRUITINGNCT06732089

Digital Interventions for Adults with Treatment-Resistant Depression: a Pilot Study

The goal of this observational study is to learn about remote mental health monitoring technology for adults with treatment-resistant depression. The main question it aims to...

Sponsor: Unity Health TorontoEnrolling: 2001 location
RECRUITINGNCT06804525

LHC-CIDI-5 in Hong Kong

The World Health Organization Composite International Diagnostic Interview-5th (CIDI-5) is a standardized diagnostic tool used to assess the prevalence of mental and substance use...

Sponsor: The University of Hong KongEnrolling: 25001 location
RECRUITINGNCT07479758

Biomarker Research on Ultra-High-Field MRI Combined With Visual Perception Assessment in the Diagnosis and Treatment...

This is an observational study aiming to screen biomarkers associated with the diagnosis and treatment outcomes of severe mental disorders (MDD/major depressive disorder,...

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang UniversityEnrolling: 3201 location
RECRUITINGNCT06624137

Computer Game, Qualitative, and MEG/EEG Assessment of Serotonergic Psychedelics

This is an observational study which does NOT directly administer a psychedelic substance but rather recruits participants who are already participating in another clinical trial...

Sponsor: Yale UniversityEnrolling: 2002 locations
RECRUITINGNCT07402356

VR Pupillometry in Cognitive Impairment

With disease-modifying therapies emerging for dementia and related conditions, identifying cognitive decline as early as possible is increasingly important. This prospective,...

Sponsor: Max-Planck-Institute of PsychiatryEnrolling: 1401 location

Frequently Asked Questions

There are currently 9 clinical trials for Major Depressive Disorder (mdd), with 9 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Major Depressive Disorder (mdd), review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 1 Phase 3 trials for Major Depressive Disorder (mdd), representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.